The Joint National Committee 7 defines resistant hypertension as failure to achieve goal BP (140/90 mm Hg for the overall population and 130/80 mm Hg for those with diabetes mellitus or chronic kidney disease) when a patient adheres to maximum tolerated doses of 3 antihypertensive drugs including a diuretic. 11 This definition does not apply to patients who have been recently diagnosed with hypertension. 12 Moreover, resistant hypertension is not synonymous with uncontrolled hypertension. Uncontrolled includes all hypertensive patients who lack BP control under treatment, namely, those receiving an inadequate treatment regimen, those with poor adherence, and those with undetected.
secondary hypertension, as well as those with true treatment resistance. By this definition, patients with resistant hypertension may achieve BP control with full doses of 4 or more antihypertensive medications. 13, 14 Although the definition of resistant hypertension is arbitrary relative to the number of antihypertensive medications required, the patients who are at high risk of having reversible causes of hypertension and/or patients who, because of persistently high BP levels, may benefit from special diagnostic or therapeutic considerations. 13 The prevalence of resistant hypertension in the general population is unknown because of an inadequate sample size of published studies as well as the feasibility of doing a large enough prospective study that would answer the question. 15, 16 Small studies, however, demonstrate a prevalence of resistant hypertension that ranges from 5% in general medical practice to 50% in nephrology clinics 15 . Based on data from the National Health and Nutrition Examination Survey, 2003 to 2004, 58% of people being treated for hypertension achieve BP levels 140/90 mm Hg; 6 control rates among those with diabetes mellitus or chronic kidney disease are 40% (6, 17) . In Europe, the situation is worse, with control rates among treated hypertensive patients between 19% and 40% in 5 large countries. 7 Such data suggest that resistant hypertension is more common than appreciated; however, accurate estimates are not possible, as control rates under treatment are affected by many factors.
"Pseudo-Resistance"
The term "pseudo-resistance" refers to lack of BP control with appropriate treatment in a patient who does not have resistant hypertension. Several factors contribute to elevated BP readings and produce the perception of resistant hypertension (Table 1) . [12] [13] [14] [15] [16] Such factors include the following: 1) suboptimal BP measurement technique; 2) the white-coat effect; and 3) poor adherence to prescribed therapy. 13, 14 Several common mistakes often produce falsely elevated BP readings. Such mistakes include (1) not allowing the patient to sit quietly for adequate time, (2) taking single instead of triple readings, (3) using cuffs that are too small for the arm, (4) recent smoking, and (5) not fully supporting the arm at heart level. 12, 13, 16 In older patients, the presence of heavily calcified or arteriosclerotic arteries that cannot be fully compressed is common and results in overestimation of intra-arterial BP. 12, 16 The "white-coat effect," defined as an elevation of BP during a clinic visit resulting in higher office readings than at home or ambulatory BP readings, 17 is another cause of pseudo-resistance. Identification of patients who have the white-coat effect either having qualified nonphysician personnel (i.e., nurses), perform office measurements or using an automated device with the patient alone in the room is useful, determination of BP under treatment with home or ambulatory measurements 19, 20 Recommendations on the modification and intensification of antihypertensive regimens for a given patient taking 3 or more drugs is based on pharmacological principles in the context of the underlying pathophysiology that portends hypertension, clinical experience, and available treatment guidelines. The present rationale for intervention in resistant hypertension (Fig. 2) is to ensure that all possible mechanisms for BP elevation are blocked. 4. Closely follow-up non-adherent patients to ensure their compliance.
C. Identify and reverse factors contributing to true resistance.
1. Specifically ask the patient about use of any pharmacological agents that may increase BP; in case of identification of such a substance, discontinue or minimize its use.
2. Evaluate the amount of alcohol intake and counsel the patient on the benefits of ceasing alcohol consumption.
3. Perform a reliable evaluation of dietary salt intake and recommend sodium restriction to 100 mmol (2.4 g) per day.
4. Assess the degree of obesity, abdominal obesity, and physical activity and recommend weight reduction and regular aerobic exercise (at least 30 min/ day, most days of the week).
5. Evaluate the level of renal function with estimation of glomerular filtration rate and modify treatment accordingly.
6. Perform a thorough search for secondary hypertension; if an identifiable cause is present, treat accordingly or refer the patient to a hypertension center.
D. Treat aggressively with optimal doses of appropriate antihypertensive medications (including drug combinations) according to patient characteristics.
E. Refer the patient to a hypertension specialist if BP control is not achieved.
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B. Management of resistant hypertension beyond pharmacotherapy
Despite the all above mentioned pharmacological measures a good number of patients failed to achieve the BP goal, 20-30% of patients continue to have resistant hypertension even while on optimal medical regimens. There is no approved therapy for patients with resistant hypertension. But the good news is that there are two devices therapy namely I. Baroreflex activation therapy and II.
Renal denervation therapy open the new era for achieving BP goal in resistant hypertension.
I. Baroreflex activation therapy
What Is the Baroreflex?
Carotid Baroreceptors Stimulation
Baroreflex or baroreceptor reflex are the terms used to describe the body's rapid response system for dealing with changes in blood pressure. The human body has its own physiologic mechanisms for sensing changes in blood pressure and controlling blood pressure. This natural system is largely located in the brain, as well as the walls of the carotid arteries, the vessels in the neck that supply blood to the brain. Pressure sensors, called baroreceptors, are found on the carotid artery and in the carotid sinus. These sensors measure and report blood pressure to the brain, which compares it to the needs of the body. For example, higher blood pressure is good for exercising, while lower blood pressure is appropriate during sleep or other periods of reduced activity. How do the Baroreceptors Control Blood Pressure? If the sensors report higher-than-needed blood pressure to the brain, the brain sends signals to other parts of the body to lower blood pressure, including the heart, vessels and kidneys.
Rheos Hypertension (HT) Therapy is a new medical device-based treatment for drug resistant hypertension. The Rheos HT System uses the CVRx patented Baroreflex Activation Therapy technology to trigger the body's own natural blood pressure regulation system. The system was designed to significantly reduce blood pressure in patients who cannot control their hypertension with drug treatments and lifestyle modifications (resistant hypertension). It is considered unique because it uses the body's own natural blood pressure sensors (baroreflex) to control blood pressure. Initially, Rheos HT Therapy will serve as an adjunct to existing therapies.
The Rheos HT System includes:
1) The Rheos Implantable Pulse Generator (about size of an iPod) is placed under the skin below the collarbone in a minimally invasive surgical procedure to control and deliver the system's activation energy.
2) The Rheos Carotid Sinus Leads are thin wires with electrical contacts that conduct activation energy from the Rheos generator to the left and right carotid arteries, located in the neck.
3) The Rheos Programmer System is an external device that allows physicians to noninvasively regulate the electrical activation according to individual patient needs. 
Mechanism:
The device requires surgical implantation under collar bone 21 and two electrodes are placed in both carotid sinuses under general anesthesia, and are fully programmable after implantation to allow adjustment of stimulation parameters. The device delivers a stimulus to trigger the body's own natural blood flow regulation system to treat high BP and heart failure. The device is intended for patients with type 2 hypertension who do not respond to BP-lowering drugs. The system works in a similar fashion to a pacemaker. The activation energy is delivered from the device to the left and right carotid arteries. The Rheos device provides control and delivery of the activation energy through the Rheos carotid sinus leads. The leads conduct activation energy from the Rheos device to the left and right carotid arteries. The Rheos programmer system provides the ability to non-invasively regulate the activation energy therapy from the device to the leads. The therapy can be adjusted to meet each patient's individual needs as they change over time, providing personalized treatment (Fig. 1) . The Rheos System works by electrically activating the baroreceptors, the body's natural blood flow regulation sensors, sensors that regulate cardiovascular function (Fig. 2) . These baroreceptors are located on the carotid artery and in the carotid sinus. When activated by the Rheos System, signals are sent through neural pathways to the brain. The brain responds by modulating autonomic nervous activity and thereby lowering BP. The brain sends signals to other parts of the body to treat high BP and heart failure.
Studies:
17 patients enrolled in a multicenter study showed prior mean BP of the cohort was 189.6 ± 27. The outcomes of the US-European clinical trial [24, 25] 
Conclusions
Preliminary data suggests an acceptably safe procedure with a low rate of adverse events and supports further clinical development of baroreflex activation as a new concept to treat resistant hypertension. Reduction in BP is associated with a reduction in the risk of death, stroke, heart attack, heart failure and kidney disease. In addition to sustained BP reduction, chronic Rheos therapy in early-stage heart failure patients remodels left atrial and ventricular chambers and improves systolic function. Benefits are incremental to those achieved with aggressive medical therapy. A feasibility study is now under way to assess the potential benefit of Rheos therapy in patients with more advanced heart failure. 24, 26 II. RENAL DENERVATION THERAPY Activation of renal sympathetic nerves is key to pathogenesis of essential hypertension. Renal sympathetic nerves contribute to development and perpetuation of hypertension, and sympathetic outflow to the kidneys is activated in patients with essential hypertension. 27 Efferent sympathetic outflow stimulates renin release, increases tubular sodium reabsorption, and reduces renal blood flow. 28 Afferent signals from the kidney modulate central sympathetic outflow and thereby directly contribute to neurogenic hypertension. [29] [30] [31] Nonselective surgical sympathectomy was effectively used as a treatment of severe hypertension before antihypertensive drugs became generally available. 32, 33 Recently developed endovascular catheter technology enables selective denervation of the human kidney, with radiofrequency energy delivered in the renal artery lumen, accessing the renal nerves located in the adventitia of the renal arteries. A first-in-man study of this approach 34 showed successful renal denervation with reduction of sympathetic activity and renin release in parallel with reductions of central sympathetic outflow. Safety and feasibility trials of this procedure identified substantial reductions of blood pressure without substantial procedure-related complications. 35 
Procedures

Symplicity catheter method:
For patients randomly assigned to undergo renal denervation, the femoral artery was accessed with the standard endovascular technique and the Symplicity catheter was advanced into the renal artery and connected to a radiofrequency generator 35 . Four-to-six discrete, low-power radio frequency treatments were applied along the length of both main renal arteries. Participants were given heparin to achieve an activated clotting time of more than 250 sec. Intra procedural diffuse visceral pain that was restricted to the duration of energy delivery was managed with intravenous anxiolytics and narcotics.
Other methods: Renal sympathetic denervation can also be done by others methods like 1. Vessix V2 Renal Denervation System™ where Bipolar RF systems deliver energy using the electrical phenomena of ohmic resistive heating to the adjacent tissue and deliver electrical energy between two electrodes, which in the case of the V2 catheter are within a few millimeters of each other. The V2 confines its energy delivery to an area very close to the two electrodes and moreover, thermistors mounted at each electrode pair allow for precise monitoring and temperature control at each independent electrode pair. This delivery of energy causes thermal heat to perfuse through the artery wall into the adventitia layer of the artery and results in denervation of the target renal sympathetic nerves. 
Studies about renal denervation therapy
Studies on Renal Denervation Therapy 
Conclusions
Hypertension is a major public health problem and the prevalence of resistant hypertension remains high with available drugs with good compliance and optimal doses. But recently developed intervention and device therapies mitigate the problems of resistant hypertension. One is Baroreflex activation therapy and another one is Renal denervation therapy. It is very important to rule out the 'pseudoresistant' hypertension and confirm the diagnosis of resistant hypertension before treating by these methods. In Baroreflex activation therapy BP was reduced by altering the body's own physiological regulatory system for hypertension by implanting a device (The Rheos HT System) like a pace maker. As it does not release any drug therefore no or very minimum procedure related adverse events. Renal denervation therapy where sympathetic nerves along the both renal arteries are denervated by catheter based low dose radiofrequency ablation.
Both the procedures are safe and effective. They not only reduce the BP but also reduce the hypertensive related complications.
